Featured Case Study:
A summer misadventure; patient safety issues during vacations because of the overconfidence of the patient.
A 49 y/o drenched male with DM1 of 22 years duration was brought to the emergency department by his wife, who was also drenched. She saw him fall out of his 14 foot boat, into the water when he stood up to land a fish he caught ...
[Read the Full Study]
Submitted by:
Paul M. Rosman, DO, FACP, FACE
Featured Case Study:
Targeting LDL-C treatment: The good, the bad, and the rated X
A 47-year-old Caucasian woman was referred for evaluation and management of a markedly abnormal lipid profile (1). Significant past medical history includes primary biliary cirrhosis (PBC) diagnosed five years previously and a 30-pack year of smoking ...
[Read the Full Study]
Submitted by:
Paul Aoun, D.O., Ph.D., Joseph P. McConnell, Ph.D., and Daniel L. Hurley, M.D.
Featured Case Study:
Too Much of a Good Thing: Thyroid Cancer Suppressive Therapy and Atrial Fibrillation
A 63-year-old man with a distant history of thyroid cancer presented to the emergency department with complaints of chest pain, palpitations and shortness of breath. He had been losing weight over the last year, which he attributed to chemotherapy ...
[Read the Full Study]
Submitted by:
John Tourtelot, MD
What's New
Potential Thyrogen Contamination

 

Pancreatitis Now An Issue for DPP-4 Inhibitors

 

Commentary on July 19 New York Times article on glucose monitor accuracy

 

AACE Expands Interactions with FDA

 

AACE and the FDA

 

Current News

Nipro Medical Corporation Issues a Voluntary Recall of All GlucoPro Insulin Syringes

January 26, 2010

Nipro Medical Corporation, Miami FL, is initiating a nationwide recall of all GlucoPro Insulin Syringes (This does not include the GlucoPro syringe specific for use with the Amigo Insulin pump). These syringes may have needles that detach from the syringe. If the needle becomes detached from the syringe during use, it can become stuck in the insulin vial, push back into the syringe, or remain in the skin after injection.

[READ MORE]

FDA Warns Consumers about Counterfeit Alli

January 18, 2010

The U.S. Food and Drug Administration is today warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit).

[READ MORE]

Patient Safety: The Joint Commission Perspective
Submitted by:
Peter B. Angood MD, FRCS(C), FACS, FCCM
[View]
NQF National Priorities Partnership: Leveraging Our Collective Efforts to Improve Safety & Quality
Submitted by:
Janet M. Corrigan, PhD, MBA
[View]
Disclaimer:
This site is for informational purposes only. For issues of an individual clinical nature please consult your physician, as medical advice will not be provided through this site. Articles and opinions expressed on the exchange do not necessarily represent the policies and/or opinions of the American Association of Clinical Endocrinologists.

 

American Association of Clinical Endocrinologists
245 Riverside Avenue Suite 200
Jacksonville, FL 32202
904.353.7878